A Registered Cohort Study on α-Synucleinopathy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Data collection, Data collection.
- Who it may be relevant to
- Registry conditions: α-synucleinopathy. Basic parameters: 30 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Registered Observational Cohort Study on α-Synucleinopathy
Overview
α-Synucleinopathy is a cluster of neurodegenerative disease with motor and non-motor symptom. The data to be collected is intended to help healthcare providers make important medical decisions concerning α-synucleinopathy, through an enhanced understanding of the natural history, progression and multi-omics datasets of α-synucleinopathy.
Detailed description
α-Synucleinopathy is a cluster of neurodegenerative disease with motor and non-motor symptom, including Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with lewy bodies (DLB). The data to be collected is intended to help healthcare providers make important medical decisions concerning α-synucleinopathy, through an enhanced understanding of the natural history, progression and multi-omics datasets of α-synucleinopathy. Datas will be accumulated retrospectively at research entry and prospectively during follow up.
Interventions
- Other Data collection
Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected - Other Data collection
Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
Primary outcome measures
- UPDRS /UMSARS scores [Time frame: Baseline]
Secondary outcome measures (9)
- H&Y stage [Time frame: Baseline]
- MoCA scores [Time frame: Baseline]
- ACE-III scores [Time frame: Baseline]
- Mean arterial pressure after 3 minutes of upright posture versus decubitus position (mmHg) [Time frame: Baseline]
- HRV (ms) [Time frame: Baseline]
- Plasma α-synuclein levels (ng/ml) [Time frame: Baseline]
- Vic [Time frame: Baseline]
- PAF (Hz) [Time frame: Baseline]
- Vic [Time frame: 1 year after Baseline]
Eligibility criteria
Inclusion criteria
- Participants with a clinical diagnosis of primary α-synucleinopathy
- Unrelated healthy controls
Exclusion criteria
- Patients with secondary α-synucleinopathy that cannot be excluded.
- Patients with other neurological disorders.
- Pregnant or lactating women.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Fujian Medical University Union Hospital — Fuzhou
Identifiers
NCT: NCT05527067 · Cohort-PDS